Adult T-cell Leukemia/LymphomaPhase 2NCT07159620
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
A Phase 2 study testing VEN (Venetoclax), Azacitidine (AZA) and Chidamide in people with Adult T-cell Leukemia/Lymphoma, run by The First Affiliated Hospital of Soochow University at 1 site in China.
Trial summary
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like… Read more about this study
- Who is it for?
- Ages 14 to 75 years
- Conditions the study is for
- Adult T-cell Leukemia/Lymphoma
- What is being tested?
- VEN (Venetoclax), Azacitidine (AZA) and Chidamide
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2025to 1 Sep 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age: >14 to 75 years (inclusive).
- Diagnosis: Patients diagnosed with ETP-ALL like disease meeting the following flow cytometry immunophenotypic criteria:
- ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate ≤75%, and positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.
- Near-ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate >75%, AND positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.
- T-ALL with myeloid mutations: FLT3, DNMT3A, STAG2, IDH1/IDH2, RUNX1, EZH2, WT1, ASXL1/ASXL2, SF3B1, TET2, BCOR, BCORL1.
- Newly diagnosed patients who have not received any prior induction therapy before enrollment (excluding hydroxyurea, dexamethasone, low-dose cytarabine, venetoclax with a cumulative dose <0.5g, and leukapheresis).
Show all 9Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
- Expected survival >6 months.
- Demonstrated capacity to understand the study and willingness to provide informed consent.
Who cannot join
- Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential
- Presence of uncontrolled active infection (including bacterial, fungal, or viral infections); concurrent active HBV, HCV, or HIV infection.
- Severe Organ Dysfunction:
- Cardiac Insufficiency: Left ventricular ejection fraction (LVEF) ≤40%, OR history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia.
- Respiratory Failure: Partial pressure of arterial oxygen (PaO₂) ≤60 mmHg. Hepatic Impairment: Total bilirubin ≥2 times the upper limit of normal (ULN), OR alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times ULN.
- Renal Impairment: Serum creatinine ≥2 mg/dL, OR creatinine clearance ≤30 mL/min/1.73m².
Show all 9Show fewer
- Hypersensitivity: History of hypersensitivity to any of the study drugs or compounds of similar chemical structure.
- Presence of central nervous system (CNS) leukemia.
- Any other condition deemed by the investigator to make the subject unsuitable for participation in this trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000
Yang Xu, 86+051267972685, xuyang1020@126.com
About this study
Official title: A Prospective Single-Arm Clinical Study of Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .
- Conditions
- Adult T-cell Leukemia/Lymphoma
- Being tested
- VEN (Venetoclax), Azacitidine (AZA), Chidamide, vindesine, Dexamethasone
- Medical subject headings
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VEN (Venetoclax)Drug
Orally
Azacitidine (AZA)Drug
Subcutaneous injection
ChidamideDrug
Orally
vindesineDrug
intravenous infusion
DexamethasoneDrug
intravenous infusion or orally
| Study group | Role | What they receive |
|---|---|---|
| Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone | Experimental | Induction Therapy Phase:
VACVP induction:Venetoclax: 100mg, d1, 200mg, d2, 400mg, d3-d21, orally. Azacitidine,75mg/m²/day, d1-d7, subcutaneously. Chidamide,10mg, d1-d7, orally. Vindesine, 4mg, d1, intravenous infusion. Dexamethasone,9mg/m²/day, d1-d14; reduced by half on d15-d17; further reduced by half on d18-d21, intravenous infusion or orally.
Consolidation therapy:
1. alternate use of HD-MTX-Ara C and VACVP(aged 14-65, inclusive of 65); alternate use of reduced-dose MTX-Ara C and VACVP(aged 65-75, inclusive of 75);
2. allogeneic hematopoietic stem cell transplantation (HSCT). Receives: Drug: VEN (Venetoclax); Drug: Azacitidine (AZA); Drug: Chidamide; Drug: vindesine; Drug: Dexamethasone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite Complete Remission Rate（CRc） after induction therapy
Rates of complete remission (CR), and complete remission with incomplete hematologic recovery (CRi)
Measured: Time from the completion of induction and before consolidation therapy（up to 42 days）
Secondary outcomes (5)
Overall survival（OS）
Time from the date of enrollment to death from any cause or the last follow-up
Measured: 2 years
Relapse-Free Survival(RFS)
The duration from the date of the first complete remisson to the occurrence of relapse, death from any cause, or the last follow-up.
Measured: 2 years
duration of remission (DOR)
Time between the first remission and relapse
Measured: 2 years
AE
Adverse events during the chemotherapy treatment.
Measured: Within 30 days after the last chemotherapy
MRD
Percentage of participants who converted to MRD < 10^-4 by flow cytometry
Measured: At the end of induction（up to 42 days）, 1 cycle of consolidation（up to 42 days）, 2 cycle of consolidation （up to 42 days）and the end of consolidation（up to 42 days）
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start1 Sep 2025
- Primary completion1 Sep 2028 (estimated)
- Study completion1 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult T-cell Leukemia/LymphomaStudies of the same condition, open and under way.
- More trials run by The First Affiliated Hospital of Soochow UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07159620
- Sponsor's protocol ID
- 2025662
- Status last verified
- Oct 2026
- First submitted
- 26 Aug 2025
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single-Arm Clinical Study of Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
- ClinicalTrials.gov ID
- NCT07159620
- Acronym / sponsor ID
- 2025662
- Conditions
- Adult T-cell Leukemia/Lymphoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- The First Affiliated Hospital of Soochow UniversityUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 1 Sep 2028 (estimated)
- Study completion
- 1 Sep 2030 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone | Experimental | Drug: VEN (Venetoclax), Drug: Azacitidine (AZA), Drug: Chidamide, Drug: vindesine, Drug: DexamethasoneInduction Therapy Phase: VACVP induction:Venetoclax: 100mg, d1, 200mg, d2, 400mg, d3-d21, orally. Azacitidine,75mg/m²/day, d1-d7, subcutaneously. Chidamide,10mg, d1-d7, orally. Vindesine, 4mg, d1, intravenous infusion. Dexamethasone,9mg/m²/day, d1-d14; reduced by half on d15-d17; further reduced by half on d18-d21, intravenous infusion or orally. Consolidation therapy: 1. alternate use of HD-MTX-Ara C and VACVP(aged 14-65, inclusive of 65); alternate use of reduced-dose MTX-Ara C and VACVP(aged 65-75, inclusive of 75); 2. allogeneic hematopoietic stem cell transplantation (HSCT). |
Who may qualify
- Ages
- 14 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (9 listed)
- Age: >14 to 75 years (inclusive).
- Diagnosis: Patients diagnosed with ETP-ALL like disease meeting the following flow cytometry immunophenotypic criteria:
- ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate ≤75%, and positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.
- Near-ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate >75%, AND positive for at least one myeloid/stem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.
- T-ALL with myeloid mutations: FLT3, DNMT3A, STAG2, IDH1/IDH2, RUNX1, EZH2, WT1, ASXL1/ASXL2, SF3B1, TET2, BCOR, BCORL1.
Key exclusion criteria (9 listed)
- Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential
- Presence of uncontrolled active infection (including bacterial, fungal, or viral infections); concurrent active HBV, HCV, or HIV infection.
- Severe Organ Dysfunction:
- Cardiac Insufficiency: Left ventricular ejection fraction (LVEF) ≤40%, OR history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia.
- Respiratory Failure: Partial pressure of arterial oxygen (PaO₂) ≤60 mmHg. Hepatic Impairment: Total bilirubin ≥2 times the upper limit of normal (ULN), OR alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times ULN.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VEN (Venetoclax)Orally | Drug | Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone |
| Azacitidine (AZA)Subcutaneous injection | Drug | Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone |
| ChidamideOrally | Drug | Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone |
| vindesineintravenous infusion | Drug | Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone |
| Dexamethasoneintravenous infusion or orally | Drug | Venetoclax Combined with Azacitidine, Chidamide, Vindesine, and Dexamethasone |
Primary outcome
Composite Complete Remission Rate（CRc） after induction therapy
Time frame: Time from the completion of induction and before consolidation therapy（up to 42 days）
Rates of complete remission (CR), and complete remission with incomplete hematologic recovery (CRi)
5 secondary outcomes
Overall survival（OS）
Time frame: 2 years
Relapse-Free Survival(RFS)
Time frame: 2 years
duration of remission (DOR)
Time frame: 2 years
AE
Time frame: Within 30 days after the last chemotherapy
MRD
Time frame: At the end of induction（up to 42 days）, 1 cycle of consolidation（up to 42 days）, 2 cycle of consolidation （up to 42 days）and the end of consolidation（up to 42 days）
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Adult T-cell Leukemia/Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
RecruitingPhase 1
A Phase I Dose Finding Study of MB-CART2219.1
Lymphoma, CLL
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing VEN (Venetoclax), Azacitidine (AZA) and Chidamide in people with Adult T-cell Leukemia/Lymphoma, run by The First Affiliated Hospital of Soochow University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yang Xu (86+051267781850, xuyang1020@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite Complete Remission Rate（CRc） after induction therapy (time frame: Time from the completion of induction and before consolidation therapy（up to 42 days）). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.